InVasc Therapeutics Receives nearly $400,000 in Two Phase 1 SBIR Grants

InVasc Therapeutics, Inc., a Tucker, Georgia-based biopharmaceutical company developing drugs to mitigate risks associated with cardiometabolic diseases, has been awarded two Small Business Innovations Research (SBIR) Phase 1 grants by the National Institutes of Health
The aggregate funding from these grants is nearly $400,000.
One grant is to continue research and development of small molecule drugs for the prevention and treatment of hypertension and stroke based on derivatives of alpha lipoic acid. The second grant is to advance the discovery and development of inhibitors of myeloperoxidase for use in treating or preventing acute vascular or inflammatory events.
The company plans to file an IND later this year for its INV-144 drug aimed at reducing proteinuria in hypertensive diabetic patients. 

Join the discussion